Comparative Evaluation of Mispa i2 and Ichroma Systems with Manual Latex Agglutination for Anti-Streptolysin O Measurement in Clinical Laboratories
DOI:
https://doi.org/10.65420/sjphrt.v2i3.168Keywords:
Streptococcus pyogenes, Anti-Streptolysin O (ASO), Mispa i2, Ichroma, Latex Agglutination, Clinical DiagnosisAbstract
Streptococcus pyogenes (Group A Streptococcus) is a common bacterium responsible for pharyngitis, with the potential for serious post-infectious complications such as rheumatic fever and glomerulonephritis. Accurate laboratory detection of anti-streptolysin O (ASO) antibodies is critical for clinical diagnosis and management. This study aimed to evaluate the performance of the Mispa i2 and Ichroma automated analyzers against the conventional manual latex agglutination method in measuring ASO titers. A cross-sectional study was conducted on 20 serum samples from patients presenting with symptoms suggestive of streptococcal infection. Results indicated that the Mispa i2 analyzer showed the highest diagnostic yield, identifying 16 positive cases (80%), followed by the Ichroma system with 13 cases (65%), while the rapid latex test identified 12 cases (60%). The findings suggest that the Mispa i2 analyzer provides superior diagnostic accuracy, simplicity, and reproducibility, making it a suitable choice for routine ASO titration in clinical microbiology laboratories.
References
Ahmed, M. K. (2022, December 21). Anti-Streptolysin O (ASO) Test: Principle, Procedure and Interpretation.
[2] Alshawish, F. M. B. M., Abdala, B. A. F., Arqeeq, M. A. M., & Salem, M. O. A. (2025). Phytochemical Profiling screening and Evaluation of Their Multi-target Biological Potentials of Catha edulis Ethanolic Extract. Al-Imad Journal of Humanities and Applied Sciences (AJHAS), 47-53.
[3] Ayoub, E. M., & Wannamaker, L. W. (1962). Evaluation of the streptozyme test for the detection of streptococcal antibodies. Pediatrics, 29(4), 527–535.
[4] Ben Hsin, M. A. M., Emsaed, H. A. M., Abujarida, A. R., Sauf, M. A., Soof, S. A., & Salem, M. O. A. (2025). A Study on the Isolation and Identification of Bacteria in Patients with Urinary Tract Infections in Libyan Laboratories. Afro-Asian Journal of Scientific Research (AAJSR), 1(4), 1-10.
[5] Bhave, C., Kinikar, A., Sani, S., Agarwal, M., & Amdekar, P. C. (1991). Epidemiology of streptococcal infection with reference to rheumatic fever. Indian Pediatrics, 28(12), 1503–1508.
[6] Bisno, A. L., Gerber, M. A., Gwaltney, J. M., Kaplan, E. L., & Schwartz, R. H. (2002). Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clinical Infectious Diseases, 35(2), 113–125.
[7] Boditech Med Inc.’s Technical Services. (2021, July 28). Document No.: INS-AS-EN Revision date: July 28, 2021 (Rev. 07).
[8] Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005). The global burden of group A streptococcal diseases. The Lancet Infectious Diseases, 5(11), 685–694.
[9] Centers for Disease Control and Prevention. (n.d.). Group A strep diseases home page and related sites. https://www.cdc.gov/groupastrep/index.html;
[10] E. W. (1932). Antigenic properties of a hemolytic streptococcal toxin associated with hemolysis. Journal of Experimental Medicine, 55(2), 267–280.
[11] Comparison of latex and hemolysin tests for the determination of streptolysin O (ASO) antibody. (1989). Journal of Clinical Pathology, 41(12), 1331–1333.
[12] Efstratiou, A. (2000). Group A streptococci in the 1990s. Journal of Applied Microbiology, 89(s1), 40S–49S.
[13] Efstratiou, A., & Lamani, T. (2016, February 10). Epidemiology of Streptococcus pyogenes. In Streptococcus pyogenes: Basic biology of clinical manifestations. University of Oklahoma Health Sciences Center. PMID: 26866237.
[14] Fernando, M. A., et al. (1990). Anti-streptolysin O titers in a rural population in Ceylon. Journal of Tropical Medicine and Hygiene, 93(2), 112–117.
[15] Gerber, M. A., Shulman, S. T., & Greene, M. (1990). Evaluation of a new latex agglutination test for the detection of streptolysin antibodies. Journal of Clinical Microbiology, 28(6), 1361–1364.
[16] Guilherme, L., Ferreira, F. M., Koller, K. F., Postol, E., & Khalil, G. (2013). A vaccine against Streptococcus pyogenes: Potential for prevention of rheumatic fever and rheumatic heart disease. American Journal of Cardiovascular Medicine, 13(1), 1–4.
[17] Hayney, M., et al. (2018). Antimicrobial resistance in Streptococcus spp. Microbiology Spectrum, 6(2), 1–12.
[18] Kadak, A. E., & Salem, M. O. A. (2020). Antibacterial Activity of Chitosan, Some Plant Seed Extracts and Oils Against Escherichia coli and Staphylococcus aureus. Alinteri Journal of Agriculture Sciences, 35(2), 144–150. doi: 10.47059/alinteri/V35I2/AJAS20086
[19] Khalil, R. A. A., Salem, I. A. S., & Salem, M. O. A. (2025). A Biochemical Study on the Effect of Alcoholic and Aqueous Extracts of Plantago ovata Leaves in Inhibiting the Growth of Antibiotic-Resistant Bacteria. Al-Imad Journal of Humanities and Applied Sciences (AJHAS), 1(2), 38-46.
[20] Klein, G. C. (1974). Manual of Clinical Immunology. American Society for Microbiology.
[21] Lepoutre, A., Doloy, A., Bidet, P., Leblond, A., Perrocheau, A., Bingen, E., et al. (2011). Epidemiology of invasive Streptococcus pyogenes infections in France. Journal of Clinical Microbiology, 49(12), 4094–4100.
[22] Low, D. E. (2016). Nonpneumococcal streptococcal infections and rheumatic fever. In L. Goldman & A. I. Schafer (Eds.), Goldman-Cecil Medicine (25th ed., chap. 290). Elsevier Saunders.
[23] MISPA-i2 Specific Protein Analyzer. (2021, August 22). Technical Review.
[24] Nelson, G. E., Pondo, T., Toews, K., Farley, M. M., Lindegren, M. L., Lynfield, R., Harrison, L. H., Weites, S., Schaffner, W., & Beall, B. (2016). Epidemiology of invasive group A streptococcal infections in the United States, 2005–2012. Clinical Infectious Diseases, 63(4), 478–486.
[25] O'Loughlin, R. E., Roberson, A., Cieslak, P. R., et al. (2007). The epidemiology of invasive group A streptococcal infection and potential vaccine implications, United States, 2000–2004. Clinical Infectious Diseases, 45(7), 853–862.
[26] Public Health Agency of Canada. (2001, September 26). Streptococcus pyogenes - Pathogen Safety Data Sheets. Government of Canada.
[27] Qotbi, A. A., Habib, N. M., & Al, S. E. (2012). Antistreptolysin O titer in health and disease: Levels and significance. Arab, Egypt.
[28] Salem, M. (2024). Antimicrobial Activity of Aqueous Methanolic Extract of Lichen (Usnea barbata) Against Escherichia coli and Staphylococcus aureus. Libyan Journal of Ecological & Environmental Sciences and Technology, 6(01), 19-23.
[29] Salem, M., & Salem, I. (2025). Antimicrobial Polymers: Mechanisms of Action and Applications in Combating Antibiotic Resistance. Al-Imad Journal of Humanities and Applied Sciences (AJHAS), 1(1), 12-15.
[30] Salem, M. O. A., & Alhadad, A. A. (2026). Phytochemical Profiling and In Vitro Antimicrobial Potential of Hypericum decaisneanum Coss. Aerial Parts Endemic to Bani Waleed, Libya. Libyan Open University Journal of Applied Sciences (LOUJAS), 2(1), 97-103.
[31] Salem, M. O. A., Ahmed, G. S., Abuamoud, M. M. M., & Rezgalla, R. Y. M. (2025). Antimicrobial Activity of Extracts of Dandelion (Taraxacum officinale) Against Escherichia coli and Staphylococcus aureus: Mechanisms, Modern Insights, and Therapeutic Potential. Libyan Journal of Medical and Applied Sciences, 3(2), 37-40.
[32] Salem, M. O. A., & Lakwani, M. A. S. (2024). Determination of Chemical Composition and Biological Activity of Flaxseed (Linum usitatissimum) Essential Oil. Journal of Biometry Studies, 4(2), 91-96.
[33] Sen, A., & Ramanan, A. V. (2014). How to use anti-streptolysin O titer. Archives of Disease in Childhood - Education and Practice, 99(6), 231–237.
[34] Soof, S. A., Sauf, M. A., Salim, A. A. A., & Salem, M. O. A. (2025). GC-MS Quantification of Bioactive Isothiocyanates in Sinapis alba Essential Oil and Validation of Rapid Bactericidal Kinetics Against Clinically Relevant Pathogens. Scientific Journal for Publishing in Health Research and Technology, 1(2), 86-93.
[35] Steer, A. C., Lamani, T., Curtis, N., & R., J. (2015). Invasive group A streptococcal disease. Current Pediatrics, 15(3), 120–125.
[36] Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Gerding, D. N., ... & Tunkel, A. R. (2005). Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clinical Infectious Diseases, 41(11), 1548–1568.
[37] Still, J. G. (1995). Antistreptolysin O latex test. The Pediatric Infectious Disease Journal, 14(4), S57–S61; Generic Assays. (2014, April 1). Antistreptolysin O Latex - 100 determinations.
[38] Teresa, J., Bogdan, T., Andrula, E., Birgitta, J., et al. (2008). Epidemiology of severe streptococcal disease in Europe. Journal of Clinical Microbiology, 46(7), 2359–2367.
[39] Tsegahun, D., Mehret, T., & Negos, T. (2019). The normal value of the anti-streptolysin O titer in rheumatoid heart disease for patients on secondary prophylaxis and healthy children in Ethiopia. ARC Journal of Cardiology, 5(1), 6–11.
